ReviewSeminars in neurology2015
Emerging therapies in traumatic brain injury.
Review in Seminars in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 121 citations in OpenAlex.
- Methylphenidate improves executive functions in patients with traumatic brain injuries: a feasibility trial via the idiographic approach.BMC neurology · 2020Trial
- Blockade of Presynaptic αNeurochemical research · 2026Article
- A Combination of Low Doses of Lithium and Valproate Improves Cognitive Outcomes after Mild Traumatic Brain Injury.Journal of neurotrauma · 2025Article
- L-carnitine: new perspectives on the management of preterm infants.Frontiers in nutrition · 2025Review
- Bioinformatics-driven exploration of key genes and mechanisms underlying oxidative stress in traumatic brain injury.Frontiers in aging neuroscience · 2025Article
- Review
- A Modern Approach to the Treatment of Traumatic Brain Injury.Medicines (Basel, Switzerland) · 2024Review
- Proteomic discovery of prognostic protein biomarkers for persisting problems after mild traumatic brain injury.Scientific reports · 2023Article
- Pharmacotherapy for Traumatic Brain Injury: The Next Generation of Clinical Trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Traumatic brain injury and immunological outcomes: the double-edged killer.Future science OA · 2023Review
- N-acetylcysteine treatment mitigates loss of cortical parvalbumin-positive interneuron and perineuronal net integrity resulting from persistent oxidative stress in a rat TBI model.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Antipsychotic Drugs: The Antithesis to Neurorehabilitation in Models of Pre-Clinical Traumatic Brain Injury.Neurotrauma reports · 2023Article
- A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases.Frontiers in neuroscience · 2023Review
- Hyaluronic Acid Scaffolds for Loco-Regional Therapy in Nervous System Related Disorders.International journal of molecular sciences · 2022Review
- Secondary Mechanisms of Neurotrauma: A Closer Look at the Evidence.Diseases (Basel, Switzerland) · 2022Review
- Krüppel-like factor 7 attenuates hippocampal neuronal injury after traumatic brain injury.Neural regeneration research · 2022Article
- Mesenchymal Stem Cell Therapy: A Potential Treatment Targeting Pathological Manifestations of Traumatic Brain Injury.Oxidative medicine and cellular longevity · 2022Review
- Empowering Data Sharing and Analytics through the Open Data Commons for Traumatic Brain Injury Research.Neurotrauma reports · 2022Article
- Effect of methylprednisolone on experimental brain edema in rats - own experience reviewed.Physiological research · 2021Review
- Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?Fundamental & clinical pharmacology · 2021Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Despite decades of basic and clinical research, treatments to improve outcomes after traumatic brain injury (TBI) are limited. However, based on the recent recognition of the prevalence of mild TBI, and its potential link to neurodegenerative disease, many new and exciting secondary injury mechanisms have been identified and several new therapies are being evaluated targeting both classic and novel paradigms. This includes a robust increase in both preclinical and clinical investigations. Using a mechanism-based approach the authors define the targets and emerging therapies for TBI. They address putative new therapies for TBI across both the spectrum of injury severity and the continuum of care, from the field to rehabilitation. They discussTBI therapy using 11 categories, namely, (1) excitotoxicity and neuronal death, (2) brain edema, (3) mitochondria and oxidative stress, (4) axonal injury, (5) inflammation, (6) ischemia and cerebral blood flow dysregulation, (7) cognitive enhancement, (8) augmentation of endogenous neuroprotection, (9) cellular therapies, (10) combination therapy, and (11) TBI resuscitation. The current golden age of TBI research represents a special opportunity for the development of breakthroughs in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.